Your Yourlocation: Home > Tiotropium bromide(136310-93-5) soft mist inhaler administration as additional treatment

The administration of tiotropium bromide(136310-93-5) soft mist inhalers has become a novel adjunctive therapy for stage 4 and 5 asthma (class B evidence) in patients with asthma who have a history of acute exacerbation at or above 18 years of age. In view of the fact that the administration of tiotropium soft mist inhaler has been officially approved for the treatment of asthma, tiotropium inhaler administration has been incorporated into the Asthma Classification Treatment Chart in the 2015 version of GINA.

There are two types of long-acting bronchodilator, one is tiotropium bromide(136310-93-5) or its representative drugs (cholinergic receptor antagonist), the other is category called β2 receptor agonists, these two are often in the the main drugs in the treatment of chronic obstructive pulmonary disease.

Specific comparison of two drugs, cholinergic receptor antagonists and β2 agonists, the two drugs are not the same, one is an antagonist is an agonist. Agonists have a characteristic is that a long time will bring the receptor desensitization or resistance. Antagonists such as tiotropium bromide(136310-93-5) have no receptor desensitization or drug resistance problems. These trials have shown that RCT studies have shown a further reduction in the risk of acute exacerbations in patients with acute cholinergic exacerbations using cholinergic receptor antagonists (17% -20%).

The use of tiotropium bromide(136310-93-5) in patients with chronic obstructive pulmonary disease there is a risk of acute exacerbations. META analysis is to put all the research together, these studies will produce some bias problems or offset the problem, which prompted us to do a better design of the COPD study, which is TIOSPIR study.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved